The private equity market entered 2020 riding 10+ years of momentum. However, the COVID-19 pandemic and associated market uncertainty have put the brakes on new deals and forced investors to alter their strategies. While some reactionary GP strategies were focused on near-term survival, we predict others are here to stay as investors adopt to the “new normal”.
A private equity-backed biopharmaceutical drug developer develops indication roadmap for phase 3 clinical trials and commercialization.Read more: PE-Backed Drug Developer Case Study
A channel dynamics evaluation to support potential mezzanine and platform provider acquisition strategy.Read more: PE Firm Evaluates the Mezzanine Market Case Study
Private equity firm assesses string of legacy brand acquisitions in OTC market.Read more: OTC Brand Diligence for PE Sponsor Case Study
A secure, fault-tolerant computing platform targets growth in edge IIoT.Read more: PE-Backed Computing Platform IIoT Case Study